The Board of Registration in Optometry voted on March 16, 2011, to adopt the following policy guidelines on the prescription of Latisse by licensed optometrists with TPA prescriptive authority.

Policy No. : 11-009

Purpose: To provide guidance to TPA-certified optometrists who seek to utilize Latisse in their optometric practice.

Policy: It is within the scope of practice of a TPA-certified optometrist to prescribe Latisse, provided that it is properly prescribed as a "therapeutic pharmaceutical agent" as defined in G.L. c. 112, s. 66B. Prescription of Latisse for cosmetic reasons or for the treatment of glaucoma is prohibited.

Discussion: Recently, the Board has been asked whether the prescription of Latisse is within the scope of practice of a TPA-certified Massachusetts optometrist. General Laws, Chapter 112, section 66B provides that:

"Any registered optometrist, qualified by examination for practice under the provisions of section 68 subsequent to January 1, 1994, duly certified in accordance with the provisions of section 68B and duly registered to issue written prescriptions in accordance with the provisions of paragraph (h) of section 7 of chapter 94C may, for the purpose of preventing, correcting, managing or treating ocular diseases or abnormalities, utilize and prescribe therapeutic pharmaceutical agents; provided, however, that nothing in this section shall be construed to permit optometric use of therapeutic pharmaceutical agents which are: (a) controlled substances as described by Title 21 U.S.C. Section 812 or in chapter 94C, except for those listed in schedule VI; (b) pharmaceutical agents administered by subdermal injection, intramuscular injection, intravenous injection, subcutaneous injection or retrobulbar injection; (c) pharmaceutical agents for the specific treatment of systemic disease; and (d) invasive surgical procedures."

G.L. c. 112, s. 66B (emphasis supplied).

The statute goes on to define "therapeutic pharmaceutical agents" as "those topical pharmaceutical agents in schedule VI required for the diagnosis, prevention, management or treatment of abnormal ocular conditions or diseases as defined in section 66, except glaucoma."

Latisse is a bimatoprost opthalmic solution 0.03% manufactured by Allergan, Inc. Information concerning the U.S. Food and Drug Administration's ("FDA") approval of Latisse can be found at the FDA's website at www.fda.gov. In Massachusetts, Latisse falls within the list of scheduled VI controlled substances. As such, pursuant to the above-cited statute, Latisse may be prescribed by TPA-certified optometrists if it is required for the "diagnosis, prevention, management or treatment of abnormal ocular conditions or diseases as defined in section 66, except glaucoma." No Massachusetts optometrist may prescribe Latisse for purely cosmetic reasons or for the treatment of glaucoma.